ClinicalTrials.gg
RecruitingNCT06844357Updated Apr 6, 2025

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

A Phase 2/3 interventional study of tirapazamine and Transarterial Embolization (TAE) in HCC, sponsored by Zhejiang Raygene Pharmaceuticals Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-06.

Sponsored by Zhejiang Raygene Pharmaceuticals Co., Ltd · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC. The results will provide valuable insights into the potential benefits of TATE as a novel treatment option for HCC.

02

Conditions studied

  • HCC
03

In context

Lead sponsor

Zhejiang Raygene Pharmaceuticals Co., Ltd is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with primary hepatocellular carcinoma according to AASLD criteria.
  • No evidence of extrahepatic , regional lymph node involvement, or vascular tumor thrombus.
  • Patients must be eligible for TAE or TACE treatment.
  • ≤ 1.
  • score ≤ 7.
  • Adequate bone marrow, liver, and kidney function is required.

Exclusion criteria

Exclusion Criteria:

  • History of liver transplantation.
  • Previous radioemblization or radiotherapy for liver tumors.
  • severe cardiovascular or renal diseases, active systemic infections.
  • hypoxia (oxygen saturation \< 92% without oxygen supplementation)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    TATE

    Patients will receive a fixed dose of 35 mg tirapazamine via hepatic arterial injection, followed by embolization with iodized oil, gelatin sponge and contrast agent suspension.

    Drug: tirapazamine · Procedure: Transarterial Embolization (TAE)

  • Experimental
    TACE

    Patients will receive cTACE with a mixture of iodized oil (10mL)and epirubicin (50 mg ), followed by embolization with gelatin sponge and contrast agent suspension.

    Procedure: TACE

Interventions

  • Intra-arterial injection into the tumor feeding artery

  • ProcedureTransarterial Embolization (TAE)

    Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia

  • ProcedureTACE

    TACE with epirubicin

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS) assessed by the Independent Radiology Committee (IRC) using mRECIST criteria.

    Time frame: 36 months

Secondary outcomes

  1. Complete Response (CR) rate

    Complete response rate (CR) assessed by IRC using mRECIST criteria

    Time frame: 36 months

  2. objective response rate (ORR)

    Time frame: 36 months

  3. duration of complete response (DOCR)

    Time frame: 36 months

  4. overall survival (OS)

    Time frame: 36 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Privacy Protection for Participants

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Apr 2029, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 25, 2025
StartActual
Mar 27, 2025
Primary completionEst.
Apr 1, 2029
CompletionEst.
Apr 1, 2029
Last update
Apr 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06844357
Lead sponsor
Zhejiang Raygene Pharmaceuticals Co., Ltd
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Mar 27, 2025
Primary completion
Apr 1, 2029 (estimated)
Completion
Apr 1, 2029 (estimated)
Last update
Apr 6, 2025

Study contacts

Bill Shen, Ph.D.
Contact
bill.shen@raygene.cn
057185131875
Gaojun Teng, M.D
principal investigator · Zhongda Hospital
Jiansong Ji, M.D
principal investigator · The Central Hospital of Lishui City

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirapazamine

Start the discussion